The use of anti-PD-(L)1 agents in the treatment of early-stage cancers is estimated to result in better health outcomes in Switzerland by reducing the number of recurrences and deaths, extending the time patients spend free of recurrences/events/disease, and reducing the number of treatments for metastatic disease. Here, CD274 is linked to metastatic neoplasm.